Evan Tang1, Oladapo Ekundayo1, John Devin Peipert2, Nathaniel Edwards1, Aarushi Bansal1, Candice Richardson1, Susan J Bartlett3, Doris Howell4, Madeline Li5, David Cella2, Marta Novak1,6, Istvan Mucsi7,8. 1. Division of Nephrology, Multi-Organ Transplant Program, University Health Network and University of Toronto, Toronto, Canada. 2. Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 3. Center for Health Outcomes Research, McGill University, Montreal, Canada. 4. Princess Margaret Cancer Center, Faculty of Nursing, University of Toronto, Toronto, ON, Canada. 5. Psychosocial Oncology, Princess Margaret Cancer Centre, Toronto, Canada. 6. Centre for Mental Health, University Health Network, Toronto, ON, Canada. 7. Division of Nephrology, Multi-Organ Transplant Program, University Health Network and University of Toronto, Toronto, Canada. istvan.mucsi@utoronto.ca. 8. Multi-Organ Transplant Unit, Toronto General Hospital, University Health Network, 585 University Avenue, 11-PMB-188, Toronto, ON, M5G 2N2, Canada. istvan.mucsi@utoronto.ca.
Abstract
OBJECTIVE: The Patient-Reported Outcomes Measurement Information System (PROMIS) aims to address the lack of generalizable and universal measure of patient-reported outcomes to assess health-related quality of life. It has not been validated for patients with chronic kidney disease. We aim to validate the PROMIS-57 and PROMIS-29 questionnaires among kidney transplant recipients. METHODS: A cross-sectional sample of stable kidney transplant recipients was recruited. Each participant completed PROMIS-57, a 57-question instrument covering seven domains-physical function, anxiety, depression, fatigue, pain, sleep disturbance, and social functioning-alongside validated legacy questionnaires [Patient Health Questionnaire (PHQ9), General Anxiety Disorder (GAD7), Edmonton Symptom Assessment Scale revised (ESASr), and Kidney Disease Quality of Life (KDQoL-36)]. PROMIS-29, a 29-question instrument, is nested within PROMIS-57 and measures the same domains. Structural validity of PROMIS was assessed with confirmatory factor analysis, reported using the Comparative Fit Index (CFI). Construct validity was assessed with known-groups comparisons. Internal consistency was evaluated with Cronbach's α and convergent validity was assessed with Spearman's Rho. Test-retest reliability was assessed through the intraclass correlation coefficient (ICC). RESULTS: Mean (± SD) age of the 177 participants was 50 (± 17), 57% were male and 55% Caucasian. Internal consistency of each domain was high (Cronbach's α > 0.88). Confirmatory factor analysis showed good structural validity for most domains (CFI > 0.95, RMSEA < 0.05). Test-retest reliability indicated good agreement (ICC > 0.6). Known-groups comparisons by clinical and socio-demographic differences were found as hypothesized. CONCLUSIONS: Our results provide evidence that PROMIS-57 and PROMIS-29 are highly reliable and valid instruments among kidney transplant recipients. We propose it as a valuable tool to assess important domains of the illness experience.
OBJECTIVE: The Patient-Reported Outcomes Measurement Information System (PROMIS) aims to address the lack of generalizable and universal measure of patient-reported outcomes to assess health-related quality of life. It has not been validated for patients with chronic kidney disease. We aim to validate the PROMIS-57 and PROMIS-29 questionnaires among kidney transplant recipients. METHODS: A cross-sectional sample of stable kidney transplant recipients was recruited. Each participant completed PROMIS-57, a 57-question instrument covering seven domains-physical function, anxiety, depression, fatigue, pain, sleep disturbance, and social functioning-alongside validated legacy questionnaires [Patient Health Questionnaire (PHQ9), General Anxiety Disorder (GAD7), Edmonton Symptom Assessment Scale revised (ESASr), and Kidney Disease Quality of Life (KDQoL-36)]. PROMIS-29, a 29-question instrument, is nested within PROMIS-57 and measures the same domains. Structural validity of PROMIS was assessed with confirmatory factor analysis, reported using the Comparative Fit Index (CFI). Construct validity was assessed with known-groups comparisons. Internal consistency was evaluated with Cronbach's α and convergent validity was assessed with Spearman's Rho. Test-retest reliability was assessed through the intraclass correlation coefficient (ICC). RESULTS: Mean (± SD) age of the 177 participants was 50 (± 17), 57% were male and 55% Caucasian. Internal consistency of each domain was high (Cronbach's α > 0.88). Confirmatory factor analysis showed good structural validity for most domains (CFI > 0.95, RMSEA < 0.05). Test-retest reliability indicated good agreement (ICC > 0.6). Known-groups comparisons by clinical and socio-demographic differences were found as hypothesized. CONCLUSIONS: Our results provide evidence that PROMIS-57 and PROMIS-29 are highly reliable and valid instruments among kidney transplant recipients. We propose it as a valuable tool to assess important domains of the illness experience.
Authors: Jacquelyn S Pennings; Clinton J Devin; Inamullah Khan; Mohamad Bydon; Anthony L Asher; Kristin R Archer Journal: Qual Life Res Date: 2019-06-06 Impact factor: 4.147
Authors: Kurt Kroenke; Timothy E Stump; Chen X Chen; Jacob Kean; Matthew J Bair; Teresa M Damush; Erin E Krebs; Patrick O Monahan Journal: J Affect Disord Date: 2020-01-23 Impact factor: 4.839
Authors: Karen M Kruger; Christopher S Constantino; Adam Graf; Ann Flanagan; Peter A Smith; Joseph J Krzak Journal: J Clin Orthop Trauma Date: 2021-11-26
Authors: Ellen B M Elsman; Leo D Roorda; Nynke Smidt; Henrica C W de Vet; Caroline B Terwee Journal: Qual Life Res Date: 2022-06-25 Impact factor: 3.440
Authors: Jing Zhang; Barry Dewitt; Evan Tang; Daniel Breitner; Mohammed Saqib; Dan Li; Rabail Siddiqui; Nathaniel Edwards; John Devin Peipert; Ron D Hays; Janel Hanmer; Istvan Mucsi Journal: Clin J Am Soc Nephrol Date: 2021-07-16 Impact factor: 10.614